rucaparib boosts pfs in brca-mutated recurrent ovarian cancer
Published 6 years ago • 170 plays • Length 3:29Download video MP4
Download video MP3
Similar videos
-
1:21
rucaparib may improve pfs in patients with ovarian cancer
-
1:51
brca and rab: prognostic biomarkers in recurrent ovarian cancer
-
2:09
rucaparib maintenance for recurrent ovarian carcinoma
-
1:44
the delivery of niraparib and rucaparib as ovarian cancer treatment options
-
1:13
comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
5:04
rucaparib and ariel3 – positive results from the phase 3 trial in ovarian cancer patients
-
5:11
defining rucaparib’s value in recurrent ovarian cancer
-
2:55
olaparib considerably increases pfs in ovarian cancer
-
9:31
ariel3: rucaparib as maintenance therapy in recurrent ovarian cancer patients
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
3:07
rucaparib maintenance and monotherapy for ovarian cancer: trial updates
-
6:12
rucaparib for recurrent ovarian cancer
-
5:15
fda d.i.s.c.o.: rucaparib in ovarian cancer
-
2:07
rucaparib in platinum-sensitive ovarian cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
4:52
cediranib plus olaparib significantly increases pfs in recurrent ovarian cancer
-
6:49
platinum-sensitive relapsed ovarian cancer: rucaparib
-
1:24
innovations in ovarian cancer treatment: parp inhibitors